VEGFA and non-small cell lung carcinoma: Radiolabeled Abs targeting EGFR (such as panitumumab and cetuximab) (10, 158–160) and VEGF/VEGFR (bevacizumab and ramucirumab) (150, 161, 162) have shown increased uptake in tumoral cells, including NSCLC (163–165).